VERAXA Biotech (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its novel BiTAC-ADC technology platform, designed to improve precision in cancer treatment by restricting activation of therapeutic agents to tumor sites. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells, achieving dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.
According to the press release, these findings further validate the potential of the BiTAC-ADC platform and complement VERAXA's BiTAC-TCE technology, giving the company two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026.
The significance of this announcement lies in the platform's potential to address a key challenge in oncology: delivering potent therapies directly to tumors while sparing healthy tissue. Traditional antibody-drug conjugates (ADCs) can cause off-target effects due to systemic release of toxic payloads. VERAXA's BiTAC-ADC platform aims to circumvent this by using two separately delivered components that only combine and activate at the tumor site, offering a new approach to cancer therapy.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a pipeline of bispecific T cell engagers, bispecific ADCs, and other innovative antibody-based therapeutics.
For more details, the full press release is available at https://ibn.fm/QiPhH. Investors can find the latest news and updates relating to VRXA in the company’s newsroom at https://ibn.fm/VRXA. The company also provides a disclaimer for forward-looking statements at http://IBN.fm/Disclaimer.
While these results are promising, VERAXA cautions that they are based on in vitro studies and may not predict clinical outcomes. The company faces risks common to drug development, including regulatory hurdles, clinical trial results, and market acceptance. As with any investment, undue reliance should not be placed on forward-looking statements.
